Q1 2025 · 13F-HR
Fairmount Funds Management LLCholdings as filed
Filed 2025-05-15 · accession 0001104659-25-049337
$644.6M
Reported value
15
Positions
2025-03-31
Period end
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 05464T104 | AXSM | AXSOME THERAPEUTICS INC | $95.1M | 14.7% | 815,176 | Common | SOLE |
| 03770N101 | APGE | APOGEE THERAPEUTICS INC | $76.5M | 11.9% | 2,048,647 | Common | SOLE |
| 00773J202 | SYRE | SPYRE THERAPEUTICS INC | $64.8M | 10.1% | 4,018,101 | Common | SOLE |
| 29337E102 | ELVN | ENLIVEN THERAPEUTICS INC | $63.0M | 9.78% | 3,202,798 | Common | SOLE |
| 670703107 | NUVL | NUVALENT INC | $51.6M | 8.00% | 727,563 | Common | SOLE |
| 252828108 | DNTH | DIANTHUS THERAPEUTICS INC | $49.0M | 7.60% | 2,700,691 | Common | SOLE |
| 92790C104 | VRDN | VIRIDIAN THERAPEUTICS INC | $46.4M | 7.21% | 3,445,813 | Common | SOLE |
| 80706P103 | SRRK | SCHOLAR ROCK HLDG CORP | $44.2M | 6.85% | 1,374,031 | Common | SOLE |
| 19240Q201 | COGT | COGENT BIOSCIENCES INC | $37.3M | 5.79% | 6,225,641 | Common | SOLE |
| 687604108 | ORKA | ORUKA THERAPEUTICS INC | $34.6M | 5.37% | 3,371,922 | Common | SOLE |
| G52694109 | KNSA | KINIKSA PHARMACEUTICALS INTL | $24.5M | 3.80% | 1,102,248 | Common | SOLE |
| 04635X102 | CATBUSD | ASTRIA THERAPEUTICS INC | $19.0M | 2.94% | 3,554,129 | Common | SOLE |
| 98937L105 | ZBIO | ZENAS BIOPHARMA INC | $15.0M | 2.32% | 1,892,806 | Common | SOLE |
| 45719W205 | IKT | INHIBIKASE THERAPEUTICS INC | $13.4M | 2.08% | 6,125,000 | Common | SOLE |
| 055477103 | BCAX | BICARA THERAPEUTICS INC | $10.2M | 1.59% | 784,170 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.